|
Non-collapsibility of standardized rate
|
|
14
|
1269
|
August 31, 2024
|
|
Effect sizes for power and evidence for effectiveness
|
|
24
|
2495
|
July 24, 2024
|
|
Use of percentage change in clinical trials
|
|
17
|
8870
|
July 22, 2024
|
|
Problems with NNT
|
|
36
|
39371
|
February 19, 2024
|
|
Discussion of Assessing Heterogeneity of Treatment Effect, Estimating Patient-Specific Efficacy, and Studying Variation in Odds ratios, Risk Ratios, and Risk Differences
|
|
33
|
13079
|
June 16, 2023
|
|
Is it legitimate to perform statistical test on test statistics such as t-values or z-scores?
|
|
5
|
4758
|
January 26, 2023
|
|
Clarification on risk magnification
|
|
7
|
4039
|
May 9, 2022
|
|
Calculating years of life lost due to COVID-19
|
|
3
|
4522
|
June 10, 2021
|
|
Calculating SMD from geometric mean titers
|
|
2
|
6221
|
May 26, 2021
|
|
Odds ratios seem to be collapsible?
|
|
17
|
8631
|
February 25, 2021
|
|
When to use absolute vs relative effect measures
|
|
13
|
44169
|
February 8, 2020
|
|
Which SD to use when calculating standardised mean differences?
|
|
1
|
4088
|
October 2, 2019
|
|
Inequality of Variances in an RCT
|
|
12
|
9140
|
December 27, 2018
|
|
Absolute risk measures from count models
|
|
6
|
8180
|
October 24, 2018
|